| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Alnylam is making significant strides in the field of RNA interference (RNAi) therapeutics, leveraging its innovative approach to create advanced medicines. The company's commitment to continuous product development positions it at the forefront of the pharmaceuticals industry. However, the complexity and challenges associated with RNAi technology could impact the pace of development and market acceptance. Overall, Alnylam's strong focus on innovation and development provides a solid basis for future growth. |
| The price action of Alnylam Pharmaceuticals (ALNY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.1 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for ALNY since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.3, and the negative at -0.2 on 2025-10-30. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (1.8) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| ALNY | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-30 | 0%(0%) | 0 | 0% | 0.1 | 1.8 | 2 | |||||||
| 2025-10-29 | 0%(0%) | 0 | 0% | 0.2 | 2.3 | -1 | |||||||
| 2025-10-28 | 0%(0%) | 0 | 0% | 0 | 1.1 | -1 | |||||||
| 2025-10-27 | 0%(0%) | 0 | 0% | -0.3 | -0.9 | -1 | |||||||
| 2025-10-26 | 0%(0%) | 0 | 0% | -0.3 | -0.8 | -1 | |||||||
| 2025-10-25 | 0%(0%) | 0 | 0% | -0.3 | -0.8 | -1 | |||||||
| 2025-10-24 | 0%(0%) | 0 | 0% | -0.3 | -0.8 | -1 | |||||||
| 2025-10-23 | 0%(0%) | 0 | 0% | -0.2 | -0.1 | -1 | |||||||
| 2025-10-22 | 0%(0%) | 0 | 0% | -0.1 | 0.3 | -1 | |||||||
| 2025-10-21 | 0%(0%) | 0 | 0% | 0.1 | 1.7 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-10-30 17:08:54 Alnylam's leadership, including its CEO, is highlighted in discussions of the company's performance and strategic direction. |
| 2025-10-30 17:08:54 The articles reflect on Alnylam's competitive position within the biotech industry, particularly against major competitors. |
| 2025-10-30 17:08:54 Alnylam is recognized for its innovative RNAi therapeutics and continuous progress in developing new medicines. |
| 2025-10-30 17:08:54 Alnylam's earnings reports have shown positive trends, with the latest results exceeding Wall Street estimates, indicating strong financial performance. |
| 2025-10-30 17:08:54 Recent articles highlight fluctuations in Alnylam Pharmaceuticals' stock price, including significant drops following earnings reports. |
| 2025-10-30 15:48:55 The raised sales guidance for 2025 suggests optimism about future revenue growth for Alnylam Pharmaceuticals. |
| 2025-10-30 15:48:55 The disclosure of a subpoena may create uncertainty and affect investor sentiment negatively. |
| 2025-10-30 15:48:55 Alnylam Pharmaceuticals reported robust earnings in Q3 with an EPS of $2.90 and significant revenue, showcasing the company's financial strength. |
| 2025-10-30 15:48:55 The stock of Alnylam Pharmaceuticals decreased despite strong earnings results, indicating market concerns. |